P&G Hygiene Q1 profit slides 34% YoY to ₹126 Cr as margins compress on input, ad costs
PAT -34.25% YoY · revenue -4.86% · margins compressing
₹891.46 Cr
-4.86% YoY
₹126.27 Cr
-34.25% YoY
14.02%
-6.3pp YoY
₹38.9
P&G Hygiene & Health Care opened FY27 with a soft print: standalone revenue from operations fell 4.9% YoY to ₹891.46 Cr and net profit dropped 34.3% to ₹126.27 Cr (EPS ₹38.90 vs ₹59.17). Sequentially too the quarter softened — revenue −5.3% and PAT −17.5% versus Q4 FY26. The bottom line, not the topline, is the story: net margin compressed to 14.2% from 20.3% a year ago and 16.1% last quarter, and PBT fell a steeper 35.9% to ₹169.63 Cr.
Q1 FY-2027 vs prior quarters
The squeeze sits on two lines. Cost of raw and packing materials consumed jumped 21.8% YoY to ₹200.24 Cr and advertising & sales-promotion spend rose 21.2% to ₹83.32 Cr — the company kept investing behind its brands even as the topline contracted, while employee costs added another 12.4%. A partial offset came from an inventory build-up (₹33.22 Cr credit) and a modest 4.3% dip in other expenses, but neither was enough to protect the margin. Part of the optical severity is base: the year-ago June quarter was an unusually strong one in which PAT had doubled to ₹192 Cr, so this quarter's decline flatters the year-ago comparison rather than signalling a fresh collapse — the ₹126 Cr print still sits above pre-spike Q1 levels.
The stock went into the print at ₹8,780, down 3.3% over the past month of trading.
The result lands against a backdrop where brokerages had already flagged margin pressure into the quarter and trimmed earnings estimates; there is no published Q1 FY27 consensus figure to grade against, and the company gives no formal guidance. On the corporate side, the board's ₹60 final dividend for FY26 (record date Aug 26) and the 62nd AGM slated for Sep 2 proceed as scheduled, and a new sales head (Gopalakrishnan) took charge from July 1 — a leadership change that coincides with the demand and margin softness. The read into Q2 is whether input-cost inflation eases and whether the elevated brand spend starts to revive a topline that has now slipped both YoY and QoQ.
W1
Whether raw & packing material inflation (+21.8% YoY to ₹200.24 Cr) eases to rebuild gross margin in Q2
W2
Payoff on elevated A&P spend (₹83.32 Cr, +21% YoY) — does it revive a topline that fell 4.9% YoY
W3
Recovery of net margin from 14.2%; brokerages model ~24-25% EBITDA margin for FY27
Standalone-only (Note 4: no subsidiary/associate/JV). Source in Lakhs, converted to Cr (÷100). totalIncome 900.89 = revenue 891.46 + other income 9.43 ✓; PAT 126.27 = PBT 169.63 − tax 43.36 ✓. No exceptional items. Year-ago Q1 FY26 (₹192.06 Cr PAT) was an unusually strong base — its profit had doubled YoY — so the −34% YoY is partly a high-base effect; no clean one-off to strip, so no adjusted figure computed.
Q1 FY27: Margin resilience on test as Street awaits traction
After a flat FY26 and Q4 sales headwind, P&G Hygiene reports Q1—watch whether new leadership (Sales Head, Feminine Hygiene VP) can reignite growth, and if cost management holds margins steady.
The setup: margin hold vs. growth restart
P&G Hygiene reported a flat FY26 (₹4290 Cr, no YoY growth) but PAT surged 19% on margin expansion. The Street will be watching whether the company can hold those margins in Q1 while cost inflation pressures persist, and whether new leadership (Sales Head, VP Feminine Hygiene appointed July–August) signals a growth turnaround or further consolidation. Q4 FY26 saw a 5% sequential sales decline, setting a low bar for Q1 expectations.
~₹1050 Cr
Low single-digit growth on base of ~₹1040 Cr (FY26 quarterly run-rate); Q4 headwind suggests muted momentum
~27%
FY26 PAT was ₹646 Cr on ₹4290 Cr sales (27% margin). Q1 test: inflation offset by cost control or margin compression?
Feminine hygiene
New VP appointed; category is high-growth segment within portfolio; watch for pricing or volume traction
What strong vs. weak looks like
A strong quarter would show high-single-digit revenue growth (₹1050+ Cr), with margin hold or slight expansion—evidence that pricing actions and cost discipline offset inflation. Feminine hygiene or core categories posting sequential acceleration would signal new leadership impact. A weak quarter would be flat-to-negative revenue growth, margin compression below 26%, and continued weakness in volume or category mix. Any guidance cut or concern on H1 trajectory would compound sentiment, given the stock's 38% drawdown from ATH and FII ownership at just 0.97%.
On track with guidance?
No explicit full-year FY27 guidance has been issued in the filings reviewed. The trajectory context: FY26 was flat on sales (likely weighed by consumer caution and cost inflation), but profitability resilience (19% PAT growth) shows the company is managing margins. Q4's 5% sequential decline suggests momentum slowed into the year-end, raising the bar only slightly for Q1. Key watch: Will new management action (Sales Head, Feminine Hygiene VP starting Aug 1–Aug) translate to visible growth by this quarter, or is H1 still in transition?
Since last quarter: filings scan
Routine corporate actions: AGM rescheduled to Sept 2 (record date Aug 26); ₹60 final dividend recommended for FY26. Management transitions (significant): CFO Gaurav Bhartia resigned (June 30) for a new P&G assignment; new CFO & ED appointed (Srividya Srinivasan, May 28). New appointments effective Aug 1–Aug: Gopalakrishnan as Sales Head (20+ years experience), Mohit Pradhan as VP Feminine Hygiene. Promoter update: Temple Trees Impex (promoter entity) transferred 1.91% stake to another promoter group entity (routine consolidation, June 19). No pledges or compliance red flags in the scan. The management churn (CFO + two key senior roles) is notable—market will assess whether new hires bring execution credibility or signal prior underperformance.
1 · Revenue trajectory & category breakup
Is Q1 revenue mid-single-digit growth, flat, or negative? Breakdown by category (feminine hygiene, oral care, home care) will show which segments are driving—or dragging. Any hint of new management traction (volume, price) or consumer slowdown.
2 · Margin resilience
Can the company hold ~27% PAT margin despite inflation, or is Q1 showing compression? Gross margin vs. opex trends will indicate pricing power vs. cost pass-through success. Watch for any guidance on H1 margin outlook.
3 · Management commentary & FY27 outlook
Will the new CFO and Sales Head provide color on turnaround priorities, H1 trading, or full-year targets? Any confidence signal on feminine hygiene growth or consumer demand recovery—or acknowledgment of near-term headwinds—will shape Street re-rating.
4 · Dividend sustainability
FY26 dividend was ₹60 per share, a 16.7% payout ratio on full-year PAT. Is this maintained in Q1 cash-flow language, or any signal of capital allocation shift? Critical for DII confidence (15.97% ownership, stable).
P&G Hygiene enters Q1 FY27 with mixed signals: solid margin resilience from FY26 offset by flat sales and Q4 momentum loss. The appointment of a new Sales Head and dedicated VP for Feminine Hygiene is the turnaround narrative—but execution is unproven, and the 38% stock drawdown reflects Street skepticism. Q1 will be the first data point under new leadership. Revenue momentum (growth or further decline?), margin hold (inflation offset?), and management confidence (outlook clarity?) will reset expectations for FY27. The 62nd AGM on Sept 2 follows hard on the heels of the result—expect dividend and capital allocation clarity there.